John Rockstroh

Learn More
Purpose of the study Previous analyses of the 2 BENCHMRK studies of ralte-gravir (RAL) vs placebo (Pbo) plus optimized background therapy (OBT) in treatment-experienced HIV-infected patients (pts) by PSS as contributed by OBT used assumptions of susceptibility to DRV/r based on prior use, since commercial phenotyping was not available. Re-analysis is now(More)
  • 1